MSD is the second instance of Bigpharma piggybacking on Tigalanol Tiglate, though in reality it is the other way round. Having researched the performance of the combination drugs, seems to me that TT is by far the more effective therapy with far more potential in applications. However Qbiotics obviously like any foundling company seems beholden to Bigpharma at this stage and hence the current strategy in pairing with seemingly inferior drugs. The current trials on head and neck cancers will add much more weight to the evidence. As well there is the as miraculous wound healing treatment. Stelfonta alone could be worth over 100 mill a year and that is just the vet market. Qbiotics is not looking at being bought out, I hope They are worth much much more than a measly $4 a share.
